Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2007

01-01-2007

Stromal Osteonectin Overexpression Is Associated with Poor Outcome in Patients with Ampullary Cancer

Authors: Mark Bloomston, MD, E. Christopher Ellison, MD, Peter Muscarella, MD, Osama Al-Saif, MBBS, Edward W. Martin, MD, W. Scott Melvin, MD, Wendy L. Frankel, MD

Published in: Annals of Surgical Oncology | Issue 1/2007

Login to get access

Abstract

Background

Osteonectin has been suggested to be important in the progression of pancreatic cancer but has not been correlated with survival. We determined the osteonectin expression and its influence on survival in patients with ampullary carcinoma.

Methods

Tissue microarrays were constructed from the tumors of 56 patients with ampullary cancer undergoing pancreaticoduodenectomy. Immunohistochemical staining for osteonectin was undertaken and compared with staining in chronic pancreatitis (n = 13) and normal pancreas (n = 19). Survival curves were created by the Kaplan-Meier method and compared by log rank analysis. Median follow-up for all living patients with ampullary cancer was 69.6 months.

Results

Osteonectin was significantly (P < .05, Fisher’s exact test) overexpressed in the stroma of ampullary cancers (90%) relative to chronic pancreatitis (62%) and normal pancreas (0%). Tumors expressing osteonectin were more likely to have nodal metastases than those lacking osteonectin expression (48% vs. 0%, P = .06, Fisher’s exact test) and showed decreased survival. Node-negative status, pylorus preservation at the time of pancreaticoduodenectomy, and lack of osteonectin expression were predictors of prolonged survival by multivariate analysis.

Conclusions

Although the importance of tumor-stroma interactions in periampullary cancers is not fully understood, our data suggest that osteonectin is an integral stromal element in ampullary cancers, and its overexpression is associated with decreased survival.
Literature
1.
Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107:1055–61PubMed
2.
Kyriakides TR, Bornstein P. Matricellular proteins as modulators of wound healing and the foreign body response. Thromb Haemost 2003; 90:986–92PubMed
3.
Sodek J, Zhu B, Huynh MH, Brown TJ, Ringuette M. Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res 2002; 43:308–19PubMedCrossRef
4.
Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000; 19:615–22PubMedCrossRef
5.
Kolb A, Kleeff J, Guweidhi A, et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther 2005; 4:740–6PubMedCrossRef
6.
Fukui R, Nishimori H, Hata F, et al. Metastases-related genes in the classification of liver and peritoneal metastasis in human gastric cancer. J Surg Res 2005; 129:94–100PubMedCrossRef
7.
Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23:3526–35PubMedCrossRef
8.
Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006; 118:2255–61PubMedCrossRef
9.
Celetti A, Testa D, Staibano S, et al. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 2005; 11:8019–27PubMedCrossRef
10.
Donati V, Boldrini L, Dell’Omodarme M, et al. Osteopontin expression and prognostic significance in non–small cell lung cancer. Clin Cancer Res 2005; 11:6459–65PubMedCrossRef
11.
Van Heek NT, Maitra A, Koopmann J, et al. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther 2004; 3:651–6PubMedCrossRef
12.
Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107:1049–54PubMedCrossRef
13.
Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004; 92:679–90PubMedCrossRef
14.
Rich JN, Shi Q, Hjelmeland M, et al. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003; 278:15951–7PubMedCrossRef
15.
Ledda MF, Adris S, Bravo AI, et al. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 1997; 3:171–6PubMedCrossRef
16.
Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. Cancer Res 2001; 61:1833–8PubMed
17.
Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003; 22:5021–30PubMedCrossRef
18.
Guweidhi A, Kleeff J, Adwan H, et al. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 2005; 242:224–34PubMedCrossRef
19.
Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 2005; 29:359–67PubMedCrossRef
20.
Zhou H, Schaefer N, Wolff M, Fischer HP. Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 2004; 28:875–82PubMedCrossRef
21.
Matsubayashi H, Watanabe H, Yamaguchi T, et al. Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of Vater. Cancer 1999; 86:596–607PubMedCrossRef
22.
AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002
23.
De Lott LB, Morrison C, Suster S, Cohn DE, Frankel WL. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Arch Pathol Lab Med 2005; 129:1100–5PubMed
24.
Yokoyama N, Shirai Y, Wakai T, Nagakura S, Akazawa K, Hatakeyama K. Jaundice at presentation heralds advanced disease and poor prognosis in patients with ampullary carcinoma. World J Surg 2005; 29:519–23PubMedCrossRef
25.
Brown KM, Tompkins AJ, Yong S, Aranha GV, Shoup M. Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg 2005; 140:529–32;discussion 532–3PubMedCrossRef
26.
Di Giorgio A, Alfieri S, Rotondi F, et al. Pancreatoduodenectomy for tumors of Vater’s ampulla: report on 94 consecutive patients. World J Surg 2005; 29:513–8PubMedCrossRef
Metadata
Title
Stromal Osteonectin Overexpression Is Associated with Poor Outcome in Patients with Ampullary Cancer
Authors
Mark Bloomston, MD
E. Christopher Ellison, MD
Peter Muscarella, MD
Osama Al-Saif, MBBS
Edward W. Martin, MD
W. Scott Melvin, MD
Wendy L. Frankel, MD
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 1/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9128-3

Other articles of this Issue 1/2007

Annals of Surgical Oncology 1/2007 Go to the issue

OriginalPaper

Complications after Extended (D2) and Superextended (D3) Lymphadenectomy for Gastric Cancer: Analysis of Potential Risk Factors

OriginalPaper

Risk Factors for Non-Sentinel Lymph Node Metastases in Patients with Breast Cancer. The Outcome of a Multi-institutional Study

OriginalPaper

Local Involvement of the Urinary Bladder in Primary Colorectal Cancer: Outcome with En-Bloc Resection

Letter to the Editor

Use of the Breast Cancer Nomogram to Predict Non-Sentinel Nodal Positivity in Patients Having Received Pre-Operative Chemotherapy

OriginalPaper

Clinical Results on Intra-arterial Adjuvant Chemotherapy for Prevention of Liver Metastasis Following Curative Resection of Pancreatic Cancer

OriginalPaper

Prognostic Groups in Colorectal Carcinoma Patients Based on Tumor Cell Proliferation and Classification and Regression Tree (CART) Survival Analysis